首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   7356篇
  免费   437篇
  国内免费   308篇
耳鼻咽喉   13篇
儿科学   97篇
妇产科学   95篇
基础医学   837篇
口腔科学   27篇
临床医学   510篇
内科学   1339篇
皮肤病学   69篇
神经病学   270篇
特种医学   130篇
外国民族医学   2篇
外科学   436篇
综合类   1159篇
预防医学   898篇
眼科学   48篇
药学   1577篇
  2篇
中国医学   428篇
肿瘤学   164篇
  2024年   76篇
  2023年   112篇
  2022年   184篇
  2021年   205篇
  2020年   180篇
  2019年   144篇
  2018年   181篇
  2017年   164篇
  2016年   222篇
  2015年   191篇
  2014年   401篇
  2013年   527篇
  2012年   372篇
  2011年   447篇
  2010年   340篇
  2009年   343篇
  2008年   363篇
  2007年   391篇
  2006年   301篇
  2005年   290篇
  2004年   252篇
  2003年   253篇
  2002年   194篇
  2001年   164篇
  2000年   189篇
  1999年   192篇
  1998年   172篇
  1997年   137篇
  1996年   126篇
  1995年   129篇
  1994年   119篇
  1993年   99篇
  1992年   85篇
  1991年   82篇
  1990年   57篇
  1989年   47篇
  1988年   44篇
  1987年   35篇
  1986年   23篇
  1985年   39篇
  1984年   38篇
  1983年   28篇
  1982年   23篇
  1981年   12篇
  1980年   14篇
  1979年   19篇
  1978年   16篇
  1977年   14篇
  1976年   16篇
  1975年   15篇
排序方式: 共有8101条查询结果,搜索用时 15 毫秒
131.
目的探讨鸦胆子油乳结合支气管动脉灌注化疗治疗局部晚期非小细胞肺癌的临床疗效。方法82例局部晚期非小细胞肺癌随机分为治疗组42例,采用鸦胆子油乳结合支气管动脉灌注化疗,对照组40例,采用单纯支气管动脉灌注化疗。结果治疗组客观疗效(CR+PR)达64.2%,对照组45%,二组比较有显著性差异(P<0.05);治疗组脑转移发生率11.9%,对照组脑转移发生率30%,二组比较有显著性差异(P<0.05)。治疗组在提高生活质量、保护免疫和骨髓功能方面优于化疗组,二组比较有显著性差异(P<0.01及P<0.05)。结论鸦胆子油乳结合支气管动脉灌注化疗治疗局部晚期非小细胞肺癌能提高客观疗效,可防止脑转移,并能提高生活质量、保护免疫功能及骨髓功能。  相似文献   
132.
采用硫代巴比妥酸(TBA)显色法测定肾上腺素(adrenalAdr)致室性心律失常(VA)后血浆及组织匀浆中脂质过氧化物(LPO)的代谢产物丙二醛(MDA)的含量,观察西米替丁(cimetidineCim)对其含量的影响。结果发现Adr诱发家兔VA后血浆及组织匀浆中MDA含量明显增加,Cim37.5mg/kgiv,能明显降低VA的发生率,推迟VA发作的时间,缩短其持续时间,并能显著抑制MDA生成。提示Adr致VA后体内脂质过氧化过程加强,Cim抗脂质过氧化可能与抗心律失常作用有关。  相似文献   
133.

Background

As a recently discovered adipokine, nesfatin-1 is conducive to insulin sensitivity, lipid profile, energy balance, and probably obesity.

Objective

The aim of the present study was to investigate the effect of upper-body resistance exercise training (RET) on nesfatin-1 levels, insulin resistance, lipid profile, and body composition in obese paraplegic men.

Methods

Twenty obese paraplegic men were randomly assigned into control and upper-body RET groups. Upper-body RET was performed for 8 weeks, 3 sessions per week at an intensity corresponding to 60–80% maximum amount of force that can be generated in one maximal contraction in 5 stations (bench press, seated rows, sitting lat pulldown, arm extension, and arm curls). Body fat percentage was determined according to 4-sites skinfold protocol of Durnin and Womersley and Siri equation. Obesity for spinal cord injury patients in the current study was set at BMI >22?kg/m2. Data were statistically analyzed by paired and independent t-test (P?<?0.05).

Results

We found significant improvements in serum levels of nesfatin-1 (21.13%), insulin sensitivity (8.95%), and high-density lipoprotein (10.87%). Other lipid profile markers, i.e. low-density lipoprotein (4.32%), cholesterol (8.20%), and triglyceride (15.10%) reduced significantly after upper-body RET. Moreover, upper-body RET led to a significant reduction in body mass index (2.36%), body fat percentage (2.79%), and waist-to-hip ratio (2.40%).

Conclusion

Upper-body RET improved insulin sensitivity, lipid profile, and body composition in paraplegic men. Serum nefastin-1 may be a potential marker of success in weight management in this population.  相似文献   
134.
Background and aimsCholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) are crucial proteins in reverse cholesterol transport. There are insufficient data on regulating these proteins by insulin therapy in type 1 diabetes mellitus (T1DM). We aimed to assess prospectively the impact of insulin therapy initiation on transfer proteins serum levels in adults with newly diagnosed T1DM.Methods and results57 adults with newly diagnosed T1DM were enrolled in the InLipoDiab1 Study. All participants were treated with subcutaneous insulin in the model of intensive insulin therapy since the diagnosis of diabetes. Serum PLTP and CETP concentrations were measured at diagnosis, after three weeks, six months, and after one year of insulin treatment, using the immunoenzymatic method ELISA.A significant decrease in PLTP and CETP concentrations were demonstrated during twelve months of insulin therapy in newly diagnosed T1DM. The dynamics of changes in the level of these proteins varied depending on the occurrence of remission after a year of the disease. In the group without remission, a significant decrease in PLTP and CETP levels appeared after six months of follow-up. The remission group was characterized by a decrease in proteins concentration only after one year of treatment. In the non-remission group, significant negative correlations were found between the daily dose of insulin and levels of PLTP and CETP.ConclusionExogenous insulin is an inhibitor of lipid transfer proteins involved in high-density lipoprotein cholesterol metabolism in the first year of treatment.  相似文献   
135.
目的 考察说明书中贮存条件要求冷藏,且须临用前即配即用的鸦胆子油乳注射液的原液和稀释后的静脉输液在室温(25 ℃)下的稳定性,为该药品的临床管理与使用提供依据。方法 模拟临床给药剂量和给药时间,考察性状、pH、渗透压、颗粒细度和油酸含量在室温下放置不同时间点的变化。结果 在室温下,鸦胆子油乳注射液原液放置72 h质量稳定,配置后静脉输液(30 mL∶250 mL 0.9%生理盐水)在24 h内各项理化指标均无明显变化。结论 鸦胆子油乳注射液在医院内部的短时间药物配送无需严格实施冷链管理;配置后静脉输液室温放置24 h稳定,无需“即配即用”。  相似文献   
136.
甘草酸磷脂复合物自乳化浓缩液的稳定性考察   总被引:1,自引:1,他引:0  
目的考察甘草酸磷脂复合物自乳化浓缩液的稳定性。方法通过低温试验(4℃),冷热循环试验(4℃,37℃)和长期试验,观察自乳化时间及乳化效果,并用HPLC测定不同条件下甘草酸的含量。结果经低温存放7 d、冷热循环7 d、常温留样6个月,自乳化浓缩液均为澄清透明溶液,无药物析出,所考察指标未见明显改变。结论甘草酸磷脂复合物自乳化浓缩液澄清透明,性质稳定。  相似文献   
137.
138.

Purpose

Results from a 6-month double-masked and a 6-month open-label study (SANSIKA) established the efficacy and safety of once-daily 0.1% cyclosporin A cationic emulsion (CsA CE) in severe keratitis due to dry eye disease (DED). This article presents results from the Post-SANSIKA study, a 24-month extension of SANSIKA assessing the sustained efficacy of CsA CE after treatment discontinuation.

Methods

Time to relapse (corneal fluorescein staining [CFS] score ≥4 [modified Oxford scale]) was assessed after treatment discontinuation in patients from the SANSIKA study who had CFS improvement from a score of 4 to ≤2 after 6 or 12 months of treatment with CsA CE.

Findings

Of 62 patients who achieved a CFS score ≤2 at the end of the SANSIKA study, 38 did not relapse and 24 (39%) relapsed during the 24-month period after CsA CE discontinuation; the latter (relapse) group comprised 35% of patients initially treated with CsA CE for 12 months in SANSIKA versus 47% of those treated for 6 months only. Patients spent the most time during the extension study at CFS scores of 1 or 2 (median duration of 8.5 weeks and 14.7 weeks per year, respectively), indicating marked improvement, and less time at scores of 3, 4, or 5 (median time, 2.0 weeks, 0 weeks, and 0 weeks per year). Of 23 patients eligible for safety analysis (ie, patients who received the study treatment at least once), 12 (52.2%) reported a total of 26 ocular adverse events (AEs). Among these, 5 ocular AEs, reported in 5 patients (21.7%), were considered related to study treatment: 3 events of mild instillation site pain in 3 patients (13.0%) and eye discharge and foreign body sensation, each reported in 1 patient (4.3%). Only 1 systemic AE (nasal congestion), reported in 1 patient (4.3%), was considered related to study treatment. None of the AEs led to treatment discontinuation.

Implications

The majority of patients who discontinued CsA CE after experiencing DED improvement in the SANSIKA study did not experience a relapse in this 24-month follow-up study; these patients spent the most time at CFS scores consistent with marked improvement. CsA CE had a favorable safety/tolerability profile over 2 years. Treatment for up to 12 months with CsA CE provides sustained improvements in patients with severe keratitis due to DED. EudraCT registration no. 2012-002066-12.  相似文献   
139.
Two near infrared cyanine dyes, DiD (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine perchlorate) and ICG (Indocyanine Green) were loaded in lipid nanoparticles (LNP). DiD-LNP and ICG-LNP presented similar physicochemical characteristics (hydrodynamic diameter, polydispersity, zeta potential), encapsulation efficiency, and colloidal stability when stored in PBS buffer. However, whereas DiD had similar biodistribution than cholesteryl-1-14C-oleate ([14C]CHO, a constituent of the nanoparticle used as a reference radiotracer), ICG displayed a different biodistribution pattern, similar to that of the free dye, indicative of its immediate leakage from the nanovector after blood injection. NMR spectroscopy using Proton NOE (Nuclear Overhauser Effect) measurements showed that the localization of the dye in the lipid nanoparticles was slightly different: ICG, more amphiphilic than DiD, was found both inside the lipid core and at particle interface, whereas DiD, more hydrophobic, appeared exclusively located inside the particle core. The ICG release rate from the particles was 7% per 1 month under storage conditions (4 °C, dark, 10% of lipids), whereas no leakage could be detected for DiD. ICG leakage increased considerably in the presence of BSA 40 g/L (45% leakage in 24 h at 100 mg/mL of lipids), because of the high affinity of the fluorophore for plasma proteins. On the contrary, no DiD leakage was observed, until high dilution of the nanoparticles which triggered their dissociation (45% leakage in 24 h at 1 mg/mL of lipids). Altogether, the subtle difference in dye localization into the nanoparticles, the partial dissociation of the LNP in diluted media, and more importantly the high ICG affinity for plasma proteins, accounted for the differences observed in the fluorescence biodistribution after tail vein injection of the dye-loaded nanoparticles.  相似文献   
140.
AimsTrans fatty acids (TFAs) are unsaturated lipids either of industrial origin or naturally occurring in ruminant meat and milk. TFAs generated through food processing (industrial) is the main source in our diet and studies provide converging evidence on their negative effect on cardiovascular health. Since April 2021, the European Commission has put into effect a regulation for TFAs providing maximum 2% of total fat in all industrially produced foods. In light of this development, we review the evidence regarding the health attributes of different types of TFAs, their dietary sources and current intakes, and we describe the history of TFA-related legislative actions in an attempt to anticipate the efficiency of new measures.Data synthesisThe PubMed database was searched including original research (observational and intervention studies), systematic reviews and meta-analyses. Scientific reports of competent authorities and organizations have also been screened.ConclusionsTrans-fat elimination provides a fine example of how evidence has led to the application of horizontal regulatory measures regarding legal food ingredients in order to protect consumers’ health. In EU Member States, TFAs currently provide on average less than 1% of energy (1%E) and intakes marginally exceed recommendations primarily among young adults. Large dietary surveys however provide evidence for additional, less-well known sources of TFAs in the diet. Raising public awareness of “hidden” trans-fat found naturally in foods such as cheese, as well as of the trans-fat generated through traditional cooking practices is needed, if the goal to eliminate trans-fat from the diet is to be met.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号